Yuan X, Hong P, Zhou J
Pulm Circ. 2025; 15(1):e70043.
PMID: 39850014
PMC: 11754236.
DOI: 10.1002/pul2.70043.
Giordano S, Ielapi J, Salerno N, Cersosimo A, Lucchino A, Laschera A
Rev Cardiovasc Med. 2024; 25(10):374.
PMID: 39484117
PMC: 11522761.
DOI: 10.31083/j.rcm2510374.
Dimitriadis K, Pyrpyris N, Iliakis P, Beneki E, Adamopoulou E, Papanikolaou A
J Clin Med. 2024; 13(17).
PMID: 39274253
PMC: 11396287.
DOI: 10.3390/jcm13175040.
Barbieri L, Tumminello G, Fichtner I, Corsini A, Santos R, Carugo S
Curr Atheroscler Rep. 2024; 26(10):589-602.
PMID: 39150672
PMC: 11393034.
DOI: 10.1007/s11883-024-01230-6.
Chong S, Mu G, Cen X, Xiang Q, Cui Y
Int J Mol Med. 2024; 53(6).
PMID: 38757360
PMC: 11093556.
DOI: 10.3892/ijmm.2024.5381.
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.
Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K
Signal Transduct Target Ther. 2024; 9(1):13.
PMID: 38185721
PMC: 10772138.
DOI: 10.1038/s41392-023-01690-3.
The Link between miRNAs and PCKS9 in Atherosclerosis.
Macvanin M, Gluvic Z, Klisic A, Manojlovic M, Suri J, Rizzo M
Curr Med Chem. 2023; 31(42):6926-6956.
PMID: 37990898
DOI: 10.2174/0109298673262124231102042914.
Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review.
Gianazza E, Macchi C, Banfi C, Ruscica M
Front Cardiovasc Med. 2023; 10:1191303.
PMID: 37378405
PMC: 10291627.
DOI: 10.3389/fcvm.2023.1191303.
Computational Design, Synthesis, and Biological Evaluation of Diimidazole Analogues Endowed with Dual PCSK9/HMG-CoAR-Inhibiting Activity.
Lammi C, Fassi E, Manenti M, Brambilla M, Conti M, Li J
J Med Chem. 2023; 66(12):7943-7958.
PMID: 37261954
PMC: 10291552.
DOI: 10.1021/acs.jmedchem.3c00279.
Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation.
Ma M, Hou C, Liu J
Front Cardiovasc Med. 2023; 10:1148486.
PMID: 36970356
PMC: 10036592.
DOI: 10.3389/fcvm.2023.1148486.
Effects of PCSK9 inhibitors on platelet function.
Raber L, Ueki Y
EuroIntervention. 2023; 18(15):1215-1217.
PMID: 36939108
PMC: 10015289.
DOI: 10.4244/EIJ-E-23-00005.
Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study.
Zhao X, Song L, Li J, Zhou J, Li N, Yan S
J Inflamm Res. 2023; 16:269-282.
PMID: 36713050
PMC: 9875734.
DOI: 10.2147/JIR.S389778.
Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents.
Wang S, Fu D, Liu H, Peng D
Front Cardiovasc Med. 2022; 9:934914.
PMID: 36324757
PMC: 9618652.
DOI: 10.3389/fcvm.2022.934914.
Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell.
Morotti A, Barale C, Melchionda E, Russo I
Int J Mol Sci. 2022; 23(19).
PMID: 36232746
PMC: 9570056.
DOI: 10.3390/ijms231911446.
Recent Update on PCSK9 and Platelet Activation Experimental Research Methods: In Vitro and In Vivo Studies.
Puteri M, Azmi N, Ridwan S, Iqbal M, Fatimah T, Rini T
J Cardiovasc Dev Dis. 2022; 9(8).
PMID: 36005422
PMC: 9409389.
DOI: 10.3390/jcdd9080258.
Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall.
Ugovsek S, Sebestjen M
J Clin Med. 2022; 11(13).
PMID: 35806908
PMC: 9267174.
DOI: 10.3390/jcm11133625.
Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes.
Song L, Zhao X, Chen R, Li J, Zhou J, Liu C
Cardiovasc Diabetol. 2022; 21(1):80.
PMID: 35596184
PMC: 9123773.
DOI: 10.1186/s12933-022-01519-3.
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis.
Cammisotto V, Baratta F, Simeone P, Barale C, Lupia E, Galardo G
Antioxidants (Basel). 2022; 11(3).
PMID: 35326219
PMC: 8945358.
DOI: 10.3390/antiox11030569.
Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis.
Puccini M, Landmesser U, Rauch U
Metabolites. 2022; 12(3).
PMID: 35323669
PMC: 8950753.
DOI: 10.3390/metabo12030226.
PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction.
Puteri M, Azmi N, Kato M, Saputri F
Life (Basel). 2022; 12(2).
PMID: 35207479
PMC: 8875594.
DOI: 10.3390/life12020190.
